$Omalizumab Improves Quality of Life (QoL) in Patients with Refractory Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) As Assessed By the Dermatology Life Quality Index (DLQI): A Post-Hoc Analysis of Percent Change from Baseline to Week 12$

Omalizumab Improves Quality of Life (QoL) in Patients with Refractory Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) As Assessed By the Dermatology Life Quality Index (DLQI): A Post-Hoc Analysis of Percent Change from Baseline to Week 12

Rationale Omalizumab, an anti-IgE monoclonal antibody, was evaluated in three Phase III trials (ASTERIA-I/II and GLACIAL); we report DLQI data from all three studies.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of allergy and clinical immunology 2015-02, Vol.135 (2), p.AB127-AB127
Hauptverfasser:	Rosén, Karin, MD, PhD, Khalil, Sam, PhD, Balp, Maria-Magdalena, MD, Maurer, Marcus, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy and Immunology Personal relationships Quality of life
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!